Open Accessmmunotherapy in the treatment of non-small cell lung cancer
Author(s) -
Ondřej Bílek,
Simona Bořilová,
Peter Grell,
Igor Kiss
Publication year - 2021
Publication title -
klinická onkologie
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.204
H-Index - 13
eISSN - 1802-5307
pISSN - 0862-495X
DOI - 10.48095/ccko2021s54
Subject(s) - immunotherapy , medicine , lung cancer , radiation therapy , chemotherapy , oncology , clinical trial , cancer
Immunotherapy with check-point inhibitors has demonstrated remarkable therapeutic benefits in many oncological diagnoses, including non-small cell lung cancer (NSCLC). Based on the data from clinical trials, it has become an important part of the NSCLC treatment algorithm. Treatment with programmed cell death protein 1 / programmed death-ligand 1 inhibitors can be indicated in various ways: as monotherapy or combination of immunotherapy with cytotox--ic T-lymphocyte antigen 4 inhibitors or in combination with other treatment modalities - chemotherapy, antiangiogenic therapy and radiotherapy. Regarding new spectrum of immune-related side effects, which require quick diagnosis and treatment, there is great urge to identify immunotherapy predictive biomarkers.